We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.76B
1-Year Est. Return
62.41%
This Fund
S&P 500
This Quarter
Est. Return
+6.07%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$4.05B
AUM Growth
+$503M
(+14%)
Cap. Flow
+$330M
Cap. Flow
% of AUM
8.14%
Top 10 Holdings %
Top 10 Hldgs %
55.84%
Holding
654
New
120
Increased
131
Reduced
191
Closed
155
Avg Time Held Equity + Options
4.2
quarters
Top 10 Avg Time Held Equity + Options
1.2
quarters
Top 20 Avg Time Held Equity + Options
1.3
quarters
Avg Time Held Equity only
4.5
quarters
Top 10 Avg Time Held Equity only
1.2
quarters
Top 20 Avg Time Held Equity only
1.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kellanova
K
|
+$269M |
| 2 |
Stericycle Inc
SRCL
|
+$141M |
| 3 |
Marathon Oil Corporation
MRO
|
+$108M |
| 4 |
ChampionX
CHX
|
+$103M |
| 5 |
Spirit AeroSystems
SPR
|
+$95.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Equitrans Midstream Corporation Common Stock
ETRN
|
+$149M |
| 2 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$81.8M |
| 3 |
Southwestern Energy Company
SWN
|
+$56.7M |
| 4 |
Union Pacific
UNP
|
+$24.2M |
| 5 |
US Steel
X
|
+$20.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 20.91% |
| 2 | Technology | 19.62% |
| 3 | Healthcare | 14.36% |
| 4 | Industrials | 11.13% |
| 5 | Consumer Staples | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
226
Axsome Therapeutics
AXSM
$8.77B
| $1.41M | 0.03% |
15,666
+548
| +4% | +$47.8K |
2022 Q1
10 quarters
|
|
227
Alkermes
ALKS
$6.77B
| $1.4M | 0.03% |
49,961
-27,039
| -35% | -$721K |
2024 Q2
1 quarter
|
|
228
Vera Therapeutics
VERA
$2.03B
| $1.39M | 0.03% |
31,452
-7,964
| -20% | -$302K |
2023 Q1
6 quarters
|
|
229
Align Technology
ALGN
$10.2B
| $1.39M | 0.03% |
5,450
+3,416
| +168% | +$806K |
2024 Q2
1 quarter
|
|
230
Autodesk
ADSK
$48.9B
| $1.38M | 0.03% |
+5,000
| New | +$1.26M |
2024 Q3
0 quarters
|
|
231
Salesforce
CRM
$192B
| $1.37M | 0.03% |
5,000
-15,000
| -75% | -$3.84M |
2023 Q4
3 quarters
|
|
232
DELISTED
Astria Therapeutics
ATXS
| $1.37M | 0.03% |
124,202
+11,537
| +10% | +$128K |
2023 Q2
5 quarters
|
|
233
People Inc
PPLI
$3.04B
| $1.35M | 0.03% |
30,475
-3,048
| -9% | -$127K |
2024 Q2
1 quarter
|
|
234
RH
RH
$2.22B
| $1.34M | 0.03% |
+4,000
| New | +$1.1M |
2024 Q3
0 quarters
|
|
235
Larimar Therapeutics
LRMR
$268M
| $1.33M | 0.03% |
202,783
-5,000
| -2% | -$40.2K |
2022 Q4
7 quarters
|
|
236
Orthofix Medical
OFIX
$376M
| $1.33M | 0.03% |
84,883
+7,885
| +10% | +$126K |
2023 Q1
6 quarters
|
|
237
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $1.31M | 0.03% |
39,260
-12,336
| -24% | -$425K |
2023 Q1
6 quarters
|
|
238
Verastem
VSTM
$753M
| $1.29M | 0.03% |
430,669
+330,280
| +329% | +$896K |
2022 Q1
10 quarters
|
|
239
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.27M | 0.03% |
17,343
+343
| +2% | +$25.8K |
2024 Q2
1 quarter
|
|
240
Treace Medical Concepts
TMCI
$263M
| $1.26M | 0.03% |
217,755
+4,779
| +2% | +$30.7K |
2022 Q1
10 quarters
|
|
241
DELISTED
Crinetics Pharmaceuticals
CRNX
| $1.26M | 0.03% |
24,693
-428
| -2% | -$22.1K |
2022 Q1
10 quarters
|
|
242
Capricor Therapeutics
CAPR
$444M
| $1.26M | 0.03% |
+82,900
| New | +$410K |
2024 Q3
0 quarters
|
|
243
Getty Realty Corp
GTY
$1.74B
| $1.26M | 0.03% |
39,582
-18,846
| -32% | -$577K |
2023 Q1
6 quarters
|
|
244
Prologis
PLD
$125B
| $1.25M | 0.03% |
9,868
-5,411
| -35% | -$671K |
2024 Q2
1 quarter
|
|
245
American Eagle Outfitters
AEO
$3.04B
| $1.23M | 0.03% |
55,000
-55,000
| -50% | -$1.13M |
2024 Q2
1 quarter
|
|
246
InflaRx
IFRX
$236M
| $1.22M | 0.03% |
797,876
+76,108
| +11% | +$116K |
2023 Q2
5 quarters
|
|
247
Alcon
ALC
$31B
| $1.2M | 0.03% |
12,009
-245
| -2% | -$23K |
2024 Q1
2 quarters
|
|
248
DELISTED
Inozyme Pharma
INZY
| $1.18M | 0.03% |
226,232
+21,014
| +10% | +$109K |
2022 Q2
9 quarters
|
|
249
Ultragenyx Pharmaceutical
RARE
$1.51B
| $1.18M | 0.03% |
21,269
-13,859
| -39% | -$706K |
2022 Q4
7 quarters
|
|
250
Sutro Biopharma
STRO
$219M
| $1.17M | 0.03% |
33,822
+6,316
| +23% | +$248K |
2023 Q3
4 quarters
|
|
Similar funds
FNBT
ACI
RC
A
CGL
CB
JCM
MPM
UBS O'Connor's Q3 2024 Portfolio in Review
As of Q3 2024, UBS O'Connor held 654 positions worth $4.05B, up 14% from $3.55B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
UBS O'Connor deployed $330M of net new capital in Q3 2024, opening 120 new positions and adding to 131 existing holdings. Its largest new stake was Kellanova: 3,778,689 shares worth $305M.
By sector, the portfolio is most concentrated in Energy at 21% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was US Steel, an estimated $20.2M trimmed.
- UBS O'Connor's largest Q3 2024 buy was Kellanova: 3,778,689 shares worth $305M.
- UBS O'Connor added most to Stericycle Inc in Q3 2024, an estimated $141M increase.
- UBS O'Connor's biggest Q3 2024 reduction was US Steel, cutting an estimated $20.2M.
- UBS O'Connor fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $149M.
- UBS O'Connor's ten largest holdings make up 56% of its $4.05B portfolio in Q3 2024.
- UBS O'Connor opened 120 new positions and closed 155 in Q3 2024.
- UBS O'Connor's portfolio value rose 14% quarter-over-quarter to $4.05B.
Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.